Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Multiple Myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: X-Ray Imaging

First Posted Date: 2020-10-08

Last Posted Date: 2024-11-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04579523

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Phase 1

Active, not recruiting

Conditions: Malignant Pleural Mesothelioma (MPM)

Interventions: Drug: cyclophosphamide
Biological: CAR T cells

First Posted Date: 2020-10-06

Last Posted Date: 2024-07-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT04577326

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Neoadjuvant Chemotherapy

Interventions: Drug: Epirubicin
Drug: Cyclophosphamid
Drug: Docetaxel
Drug: Paclitaxel

First Posted Date: 2020-10-06

Last Posted Date: 2021-08-12

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 260

Registration Number: NCT04576143

Locations: 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2

Active, not recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: cyclophosphamide
Drug: doxorubicin
Drug: prednisone

First Posted Date: 2020-09-29

Last Posted Date: 2024-10-15

Lead Sponsor: Seagen Inc.

Target Recruit Count: 82

Registration Number: NCT04569032

Locations: 🇺🇸
Stanford Cancer Center / Blood and Marrow Transplant Program, Stanford, California, United States
🇺🇸
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸
Johns Hopkins Medical Center, Washington, District of Columbia, United States

and more 48 locations

Haploidentical HCT for Severe Aplastic Anemia

Phase 2

Recruiting

Conditions: Aplastic Anemia
Bone Marrow Failure Syndrome

Interventions: Drug: Anti-Thymocyte Globulin (Rabbit)
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Drug: G-CSF
Radiation: Total Lymphoid Irradiation (TLI)
Device: CliniMACS
Biological: HPC, A Infusion
Biological: CD45RA-depleted DLI

First Posted Date: 2020-09-22

Last Posted Date: 2024-10-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 21

Registration Number: NCT04558736

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor, Adult

Interventions: Drug: FT516
Drug: Avelumab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: IL-2

First Posted Date: 2020-09-16

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 12

Registration Number: NCT04551885

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Phase 3

Recruiting

Conditions: Leukemia

Interventions: Drug: Cytarabine
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Me-CCNU
Drug: Rabbit antithymocyte globulin
Procedure: Allogeneic HSCT
Drug: Cyclosporin A
Drug: Mycophenolate Mofetil
Drug: MTX

First Posted Date: 2020-09-14

Last Posted Date: 2023-02-21

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 160

Registration Number: NCT04547049

Locations: 🇨🇳
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳
The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

and more 5 locations

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B Cell Lymphoma
Refractory Non-Hodgkin Lymphoma
Follicular Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma
Transformed Lymphoma
Burkitt Lymphoma
Lymphoplasmacytic Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: anti-CD19 CAR-T cells

First Posted Date: 2020-09-11

Last Posted Date: 2023-12-14

Lead Sponsor: C. Babis Andreadis

Target Recruit Count: 36

Registration Number: NCT04545762

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase 1

Suspended

Conditions: Recurrent Childhood Neuroblastoma
Recurrent Childhood Osteosarcoma
Recurrent Neuroblastoma
Recurrent Osteosarcoma
Refractory Childhood Neuroblastoma
Refractory Childhood Osteosarcoma
Refractory Neuroblastoma
Refractory Osteosarcoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine Phosphate
Biological: GD2-CAR-expressing Autologous T-lymphocytes
Procedure: Imaging Procedure
Procedure: Magnetic Resonance Imaging of the Heart
Procedure: Multigated Acquisition Scan
Other: Questionnaire Administration

First Posted Date: 2020-09-07

Last Posted Date: 2025-01-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 67

Registration Number: NCT04539366

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 3 locations

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Phase 2

Withdrawn

Conditions: Metastatic HPV-16 Positive Squamous Cell Anal Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Drug: Pembrolizumab (KEYTRUDA(R))
Biological: Individual Patient TCR-Transduced PBL

First Posted Date: 2020-09-03

Last Posted Date: 2021-02-01

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04536922

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy